Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 30:8:601.
doi: 10.3389/fchem.2020.00601. eCollection 2020.

Emerging Adjuvants for Cancer Immunotherapy

Hong-Guo Hu  1 , Yan-Mei Li  1   2   3
Affiliations
Review

Emerging Adjuvants for Cancer Immunotherapy

Hong-Guo Hu et al. Front Chem. .

Abstract

Cancer is a life-threatening disease, and immunotherapies have been developed as a novel, potent treatment for cancer. Adjuvants, used alone or in combination with other agents, play crucial roles in immune activation. This is necessary for cancer immunotherapy, particularly in the construction of therapeutic cancer vaccines. Adjuvants activate antigen-presenting cells and promote the presentation of antigen epitopes on major histocompatibility complex molecules, further enhancing adaptive immune responses, including cytotoxic T lymphocytes, to elicit cancer-cell death. However, the applications of adjuvants are limited by their poor efficacy or insufficient safety. In recent studies, researchers attempted to develop safe, efficacious adjuvants for cancer immunotherapy, and many compounds (including inorganic compounds, organic molecules, polymers, and colloids) have been identified and optimized as agonists of various pathways. In this review, we focus on the discovery and structural design of emerging adjuvants and discuss how these findings benefit healthcare.

Keywords: adjuvant; cancer; immune activation; immunotherapy; pattern recognition receptors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of emerging adjuvants.
See this image and copyright information in PMC

References

    1. Aderem A., Ulevitch R. J. (2000). Toll-like receptors in the induction of the innate immune response. Nature 407:228. 10.1038/35021228 - DOI - PubMed
    1. Akira S., Takeda K., Kaisho A. T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:609. 10.1038/90609 - DOI - PubMed
    1. Albin T. J., Tom J. K., Manna S., Gilkes A. P., Stetkevich S. A., Katz B. B., et al. . (2019). Linked Toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses. ACS Cent. Sci. 5, 1137–1145. 10.1021/acscentsci.8b00823 - DOI - PMC - PubMed
    1. Broz P., Monack D. M. (2013). Newly described pattern recognition receptors team up against intracellular pathogens. Nat. Rev. Immunol. 13, 551–565. 10.1038/nri3479 - DOI - PubMed
    1. Burdette D. L., Vance R. E. (2013). STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 14, 19–26. 10.1038/ni.2491 - DOI - PubMed

LinkOut - more resources